Document is current
Any future updates will be listed below
-
Authors
Agrawal, Neha https://orcid.org/0000-0001-8506-6559
Ates, Louis S. https://orcid.org/0000-0002-2953-8010
Schille, Stefan A. https://orcid.org/0000-0001-5395-8368
Chaturvedi, Anuhar https://orcid.org/0000-0002-9597-3010
Vogt, Janina
Vukovic, Natasa https://orcid.org/0000-0002-9083-2104
Dulberger, Charles L.
Vogel, Annette B.
Diekmann, Jan
Diken, Mustafa https://orcid.org/0009-0005-4391-4042
Şahin, Uğur https://orcid.org/0000-0003-0363-1564
-
Funding
Funding for this research was provided by:
This work was performed at BioNTech SE and supported by the Gates Foundation. All authors are or were employees at BioNTech.
- License Information
-
More Information
Article History
Received: 1 October 2025
Accepted: 12 May 2026
First Online: 12 June 2026
Competing interests
: All authors are or were employees at BioNTech and may hold BioNTech stock options. U.Ş. is a management board member and stock owner of BioNTech SE (Mainz, Germany). N.A., S.A.S., A.B.V., M.D. and U.Ş. are inventors on International Patent Application PCT/EP2022/071816, which relates to TB vaccine candidates. N.A., L.S.A., S.A.S., A.C., C.L.D., A.B.V., J.D., M.D. and U.Ş. are inventors on patents or patent applications relating to mRNA technology and vaccines.
